Compare
Vir Biotechnology, Inc. vs Black Diamond Therapeutics, Inc. vs Compugen Ltd vs Recursion Pharmaceuticals, Inc.
| Latest fiscal year | Vir Biotechnology, Inc. VIR | Black Diamond Therapeutics, Inc. BDTX | Compugen Ltd CGEN | Recursion Pharmaceuticals, Inc. RXRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $68.56M | $70.00M | $72.76M | $74.68M |
| Revenue growth (YoY) | -7.6% | n/a | +161.1% | +26.9% |
| Gross margin | n/a | n/a | 87.3% | 5.0% (computed) |
| Operating margin | -699.2% | 17.9% | 43.1% | -867.9% |
| Net margin | -638.9% | 32.0% | 48.6% | -863.4% |
| Net income | -$437.99M | $22.37M | $35.34M | -$644.76M |
| EPS (Diluted) | -$3.16 | $0.39 | $0.38 | -$1.44 |
| Operating cash flow | -$391.78M | $29.61M | $31.63M | -$371.81M |
| Free cash flow | -$396.61M | n/a | $31.33M | -$378.28M |
| Cash & equivalents | $232.19M | $20.99M | $90.60M | $743.29M |
| Total assets | $1.00B | $143.01M | $156.57M | $1.47B |
| Total liabilities | $237.55M | $30.80M | n/a | $343.26M |
| Shareholders' equity | $765.28M | $112.21M | $102.73M | $1.13B |
| Return on year-end equity | -57.2% | 19.9% | 34.4% | -57.0% |
| Shares outstanding | 139.47M | 57.14M | 94.55M | 528.18M |
Revenue, most recent five fiscal years
| Fiscal year | Vir Biotechnology, Inc. | Black Diamond Therapeutics, Inc. | Compugen Ltd | Recursion Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $68.56M Ended 2025-12-31 | $70.00M Ended 2025-12-31 | $72.76M Ended 2025-12-31 | $74.68M Ended 2025-12-31 |
| 1 year earlier | $74.20M Ended 2024-12-31 | $0 Ended 2024-12-31 | $27.86M Ended 2024-12-31 | $58.84M Ended 2024-12-31 |
| 2 years earlier | $86.18M Ended 2023-12-31 | n/a | $33.46M Ended 2023-12-31 | $44.58M Ended 2023-12-31 |
| 3 years earlier | $1.62B Ended 2022-12-31 | n/a | $7.50M Ended 2022-12-31 | $39.84M Ended 2022-12-31 |
| 4 years earlier | $1.10B Ended 2021-12-31 | n/a | $6.00M Ended 2021-12-31 | $10.18M Ended 2021-12-31 |